Role of Prostacyclin in the Cardiovascular Response to Thromboxane A 2
Top Cited Papers
- 19 April 2002
- journal article
- other
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 296 (5567), 539-541
- https://doi.org/10.1126/science.1068711
Abstract
Thromboxane (Tx) A 2 is a vasoconstrictor and platelet agonist. Aspirin affords cardioprotection through inhibition of TxA 2 formation by platelet cyclooxygenase (COX-1). Prostacyclin (PGI 2 ) is a vasodilator that inhibits platelet function. Here we show that injury-induced vascular proliferation and platelet activation are enhanced in mice that are genetically deficient in the PGI 2 receptor (IP) but are depressed in mice genetically deficient in the TxA 2 receptor (TP) or treated with a TP antagonist. The augmented response to vascular injury was abolished in mice deficient in both receptors. Thus, PGI 2 modulates platelet-vascular interactions in vivo and specifically limits the response to TxA 2 . This interplay may help explain the adverse cardiovascular effects associated with selective COX-2 inhibitors, which, unlike aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), inhibit PGI 2 but not TxA 2 .Keywords
This publication has 27 references indexed in Scilit:
- The α, but Not the β, Isoform of the Human Thromboxane A2 Receptor Is a Target for Prostacyclin-mediated DesensitizationPublished by Elsevier BV ,2000
- Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2.JCI Insight, 1998
- Modulation of monocyte-endothelial cell interactions by platelet microparticles.JCI Insight, 1998
- Mechanisms of platelet activation: Thromboxane A2 as an amplifying signal for other agonistsThe American Journal of Cardiology, 1991
- Redirection of prostaglandin endoperoxide metabolism at the platelet-vascular interface in man.JCI Insight, 1989
- Aspirin and Dipyridamole in the Prevention of Re-Stenosis after Percutaneous Transluminal Coronary AngioplastyNew England Journal of Medicine, 1988
- Endogenous biosynthesis of prostacyclin during cardiac catheterization and angiography in man.Circulation, 1985
- Increased Prostacyclin Biosynthesis in Patients with Severe Atherosclerosis and Platelet ActivationNew England Journal of Medicine, 1984
- Synthesis of Prostacyclin from Platelet-derived Endoperoxides by Cultured Human Endothelial CellsJCI Insight, 1980
- An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregationNature, 1976